Rigosertib Suspended Phase 1 Trials for Myelodysplastic Syndrome Treatment

IndicationsStatusPurposePhase
SuspendedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02075034Three Dosing Schedules of Oral Rigosertib in MDS Patients